1. Supplemental figures

2. Supplemental Figure 1 HSSY-II synovial sarcoma line
SSX exon expression
SW982 synovial sarcoma line
SSX exon expression
SYO-1 synovial sarcoma line
SSX exon expression
Supplemental
Figure 1

3. Multi-plate, Multi-day Validation
Supplemental
Figure 2

4. Active
Inactive
Sarcoma Lines
Compounds Tested
Supplemental
Figure 3

5. Supplemental Figure 4 hsa-miR-9-5p hsa-miR-22-3p hsa-miR-222-3p
hsa-miR-125b-5p
Supplemental
Figure 4

6. D
PI3K
Akt
mTOR
Supplemental
Figure 5

7. Supplemental Figure 6 hsa-miR-9-5p hsa-miR-100-5p hsa-miR-22-3p
hsa-miR-30a-5p
Supplemental
Figure 6

8. NSC767128
Birinapant
Supplemental
Figure 7

9. A-204 cells
Supplemental
Figure 8

10. Supplemental Figure 9 Saracatinib NSC-758872 Astrazeneca ZM-336372
WZ-4002
NSC
Dana-Farber
Supplemental
Figure 9